New drug combo trial targets Tough-to-Treat liver cancer
NCT ID NCT06855225
Summary
This study is testing a combination of two immunotherapy drugs (tremelimumab and durvalumab) with two chemotherapy drugs (gemcitabine and cisplatin) for people with an advanced, hard-to-treat form of liver cancer called combined hepatocellular-cholangiocarcinoma (cHCC-CCA). The goal is to see if this four-drug combination can shrink tumors and control the cancer. The trial will enroll about 29 adults with this specific cancer that cannot be removed by surgery or has spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.